These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33140194)

  • 1. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
    Meyers BM; Vogel A; Marotta P; Kavan P; Kamboj L; Pan J; Geadah M; Trueman D; Sabapathy S
    Can J Gastroenterol Hepatol; 2021; 2021():8811018. PubMed ID: 33681090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
    Gao J; Liu S; Li SJ; Wang R; Meng ZH; Kong XS
    Med Sci Monit; 2024 Jul; 30():e944526. PubMed ID: 39033318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ho JC; Hsieh ML; Chuang PH; Hsieh VC
    Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
    Ikeda S; Kudo M; Izumi N; Kobayashi M; Azuma M; Meier G; Pan J; Ishii M; Kaneko S
    Value Health Reg Issues; 2021 May; 24():82-89. PubMed ID: 33524900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
    Meng R; Cao Y; Zhou T; Hu H; Qiu Y
    Front Public Health; 2022; 10():794131. PubMed ID: 35433574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.